Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc.

FULCNYSE / NASDAQHealthcareSmall cap

$3.69-$0.02 (-0.5%)

Last close · Data as of Nov 20, 2026

Market cap
$224.6M
Revenue
$0.00
ROCE
-24.3%

This period includes a one-day price step on 2 Jun 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Fulcrum Therapeutics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-0.8%
3M
-4.2%
6M
Hidden
1Y
Hidden
5Y
Hidden
  • This period includes a one-day price step on 2 Jun 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

This period includes a one-day price step on 2 Jun 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Day change -$0.02 (-0.5%) from $3.71 to $3.69 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in FULC, bought on each weekday since 2021.

News & filings

What Fulcrum Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 74.9 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are more than ten times current liabilities.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.
  • This period includes a one-day price step on 2 Jun 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.

Read moreShow less

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Shares outstanding
66.6M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$224.6M
P/B
0.6x
52-week high
Hidden
52-week low
Hidden

Profitability

ROE
-21.5%
ROCE
-24.3%
ROIC
-42.4%
ROA
-20.4%

Growth

Revenue
$0.00
Revenue growth, 1Y
-100.0%
Net profit growth, 1Y
670.0%
Free cash flow
-$60.4M

Solvency

Current ratio
27.39
Debt / Equity
0.02
Debt / Assets
0.02
CFO / Net profit
0.80
Cash / Market cap
156.9%

Revenue and net profit

Revenue fell 100.0% in FY2025; net profit is the dashed line.

Fulcrum Therapeutics, Inc. revenue and net profit by fiscal year
Fulcrum Therapeutics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$6.3M-$109.9M
FY2023$2.8M-$97.3M
FY2024$80.0M-$9.7M
FY2025$0.00-$74.9M

Cash flows

FY2025: -$60.1M from operations, -$60.4M free after investment (dashed).

Fulcrum Therapeutics, Inc. operating and free cash flow by fiscal year
Fulcrum Therapeutics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$97.0M-$99.0M
FY2023-$91.0M-$91.5M
FY2024-$2.2M-$2.5M
FY2025-$60.1M-$60.4M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00-100.0%1Y
EBITDA
-$83.4M
Net profit
-$74.9M
Cash from operations
-$60.1M
Free cash flow
-$60.4M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$83.4M-$74.9M-$60.4M-21.5%-100.0%+670.0%

Monthly returns

Month-by-month returns of FULC across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$366.3M
Liabilities$17.3M
Equity$349.0M
Paid-in capital$943.0M
Retained earnings-$594.3M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; FULC highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

Not shown (no positive earnings and no EV / Sales): Fulcrum Therapeutics, Inc., Inhibikase Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Fulcrum Therapeutics, Inc.FULCthis company$224.6M—0.6x-21.5%—
Arcturus Therapeutics Holdings Inc.ARCT$228.5M-3.5x1.1x-30.7%-0.4x
Spok Holdings, Inc.SPOK$228.3M14.4x1.6x10.8%8.9x
LENZ Therapeutics, Inc.LENZ$225.8M—0.8x-28.9%—
Foghorn Therapeutics Inc.FHTX$219.6M-3.0x-2.0x68.5%-2.3x
Inhibikase Therapeutics, Inc.IKT$219.2M-4.5x1.3x-27.9%-1.5x
Voyager Therapeutics, Inc.VYGR$218.7M-1.8x1.1x-61.1%-1.5x
Utah Medical Products, Inc.UTMD$216.5M19.2x1.8x9.5%9.1x
Pro-Dex, Inc.PDEX$213.9M23.8x5.8x24.5%16.3x
Peer median—-1.8x1.2x-9.2%-0.4x

Year-to-date ROI

FULC since 1 January, against earlier years.

Historical volatility

FULC's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Fulcrum Therapeutics, Inc. operating margin by fiscal year
Fulcrum Therapeutics, Inc. operating margin by fiscal year
DateOperating margin
FY2022-1768.6%
FY2023-3952.1%
FY2024-24.8%
FY2025—
LineFY2025
Operating expensesOperating Expense$84.8M
Research and developmentResearch And Development$56.1M
Total expensesTotal Expenses$84.8M
Pretax incomePretax Income-$74.9M

Learn while you research

Academy chapters picked for Fulcrum Therapeutics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →